Therapeutics News and Research

RSS

University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle

The second phase of a clinical trial testing a new stem-cell-based therapy on injured heart muscle has been launched by researchers at The University of Texas Medical School at Houston. It is the only study site in the Texas Medical Center.

9 Dec 2009

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

Lung cancer is the leading cause of cancer mortality worldwide and lung adenocarcinoma is the most common type. Many cases of lung adenocarcinoma are attributed to a mutation in a gene for the epidermal growth factor receptor (EGFR).

9 Dec 2009

TMZ and small molecule combination appears to lower tumor resistance

University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chemotherapy drug to achieve even better results against colon cancer cells.

9 Dec 2009

Bird influenza viruses have a variety of strategies to cross the species barrier

The 2009 H1N1 influenza virus used a new strategy to cross from birds into humans, a warning that it has more than one trick up its sleeve to jump the species barrier and become virulent.

9 Dec 2009

Pfizer, Crown Bioscience team up to research and develop novel therapeutics for Asian cancers

Pfizer (PFE) and Crown Bioscience, Inc. (Crown) announced today that they have entered into a collaboration to research and develop novel therapeutics for Asian cancers. Specific treatments for Asian cancers represent an important unmet medical need as well as a significant market opportunity.

9 Dec 2009

Updated data from Allos Therapeutics' ongoing FOLOTYN study

Allos Therapeutics, Inc. today announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). These data were showcased during an oral presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA.

8 Dec 2009

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, presented data demonstrating that ACE-536 promotes formation of red blood cells through inhibition of members of the TGF-beta superfamily, at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Hemaquest Pharmaceuticals' HQK-1001 holds promise for sickle cell disease and beta thalassemia

HemaQuest Pharmaceuticals presented data from new preclinical studies and early results from clinical trials of its lead drug candidate, HQK-1001, in sickle cell disease and beta thalassemia at the annual meeting of the American Society of Hematology in New Orleans.

8 Dec 2009

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension.

8 Dec 2009

Anesiva to merge with Arcion Therapeutics

Anesiva, Inc. announced today that the stockholders of Anesiva approved the merger with Arcion Therapeutics, Inc. ("Arcion") during its December 3, 2009 shareholder meeting. In connection with the merger, Anesiva stockholders also approved a one-for-forty reverse stock split, which will be effected upon the close of the merger.

8 Dec 2009

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Cell Therapeutics, Inc. announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals.

8 Dec 2009

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

Onconova Therapeutics, Inc. today announced promising results from two clinical trials in patients with advanced Myelodysplastic Syndrome (MDS) treated with ON 01910.Na. These trials are being conducted at the National Heart, Lung, and Blood Institute (NHLBI) in Bethesda, MD, and St. Vincent’s Comprehensive Cancer Center in New York.

8 Dec 2009

SOLESTA pivotal study meets primary endpoints for fecal incontinence treatment

Q-Med AB and Oceana Therapeutics, Inc. today announced that the SOLESTA pivotal study succeeded in meeting both primary endpoints for the treatment of fecal incontinence.

8 Dec 2009

Market for personalized medicine in the United States to grow 11 percent annually, shows report

The market for personalized medicine in the United States is already $232 billion, and it is projected to grow 11 percent annually, according to a new report published today by PricewaterhouseCoopers LLP, entitled The Science of Personalized Medicine: Translating the Promise into Practice.

8 Dec 2009

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to SAR3419 – administered as a single agent – among patients with B-cell non-Hodgkin's lymphoma that is refractory to treatment with rituximab (Rituxan®).

8 Dec 2009

New pharmacology textbook released by Elsevier

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, proudly announces the early success and rapid acceptance of its recently released Pharmacology and Therapeutics: Principles to Practice, an innovative new pharmacology textbook designed to better meet the needs of today's residents and practitioners.

8 Dec 2009

Non-clinical data of CK-2017357 presented by Cytokinetics

Cytokinetics, Incorporated announced today that both a poster and an oral presentation summarizing non-clinical data regarding CK-2017357, a novel fast skeletal troponin activator, were presented at the 5th Cachexia Conference, organized by the Society on Cachexia and Wasting Disorders, being held December 5-8, 2009 in Barcelona, Spain.

8 Dec 2009

5AM Venture Management closes $200 million venture capital fund

5AM Venture Management, LLC of Menlo Park, CA and Waltham, MA is pleased to announce the closing of 5AM Ventures III, L.P., a $200 million venture capital fund focused on early-stage life science companies.

8 Dec 2009

ThermoGenesis enters into material transfer agreement with GID Group

ThermoGenesis Corp., a leading supplier of innovative products for processing and storing adult stem cells, said today it has entered into a material transfer agreement with the GID Group which has been working with ThermoGenesis to use ThermoGenesis' MarrowXpress(TM), or MXP(TM), based technology for the processing of adipose, or fatty, tissue - a rich source of adult stem cells.

8 Dec 2009

Celldex Therapeutics to present poster on its first antibody-drug conjugate product

Celldex Therapeutics, Inc. today announced that the Company’s first antibody-drug conjugate (ADC) product candidate, CDX-011 (formerly CR011-vcMMAE), for the treatment of locally advanced or metastatic breast cancer will be the subject of a poster presentation at the 2009 San Antonio Breast Cancer Symposium.

8 Dec 2009

Therapeutics News and Research

University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

TMZ and small molecule combination appears to lower tumor resistance

Bird influenza viruses have a variety of strategies to cross the species barrier

Pfizer, Crown Bioscience team up to research and develop novel therapeutics for Asian cancers

Updated data from Allos Therapeutics' ongoing FOLOTYN study

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

Hemaquest Pharmaceuticals' HQK-1001 holds promise for sickle cell disease and beta thalassemia

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Anesiva to merge with Arcion Therapeutics

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

SOLESTA pivotal study meets primary endpoints for fecal incontinence treatment

Market for personalized medicine in the United States to grow 11 percent annually, shows report

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

New pharmacology textbook released by Elsevier

Non-clinical data of CK-2017357 presented by Cytokinetics

5AM Venture Management closes $200 million venture capital fund

ThermoGenesis enters into material transfer agreement with GID Group

Celldex Therapeutics to present poster on its first antibody-drug conjugate product

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News